Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion

Swiss drugmaker Novartis announced its acquisition of Avidity Biosciences for $12 billion in cash, paying $72 per share, a 46% premium, to significantly bolster its portfolio of treatments for rare muscle disorders and expand its rare disease presence. This strategic move aims to address impending patent expirations for key Novartis drugs by integrating Avidity's clinical-stage RNA therapeutic programs for neuromuscular diseases. As part of the transaction, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded company, Spinco.

Analysis

Novartis has agreed to acquire U.S. biotech firm Avidity Biosciences for $12 billion in cash, paying $72 per share, which represents a substantial 46% premium over Avidity's closing price. This acquisition is strategically aimed at bolstering Novartis's portfolio in rare muscle disorders, an area characterized by limited treatment options and high growth potential.

This move directly addresses Novartis's impending patent cliff for blockbuster drugs such as Entresto, Xolair, and Cosentyx by integrating Avidity's clinical-stage RNA therapeutic programs. Avidity brings three experimental drug candidates for rare neuromuscular disorders, including the lead drug Del-zota for Duchenne muscular dystrophy, which are expected to seek approval by 2026 and utilize advanced RNA delivery technology.

As part of the transaction, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded entity named Spinco, to be led by Kathleen Gallagher. The acquisition also strengthens Novartis's U.S. market presence, a critical consideration given potential pharmaceutical tariff threats from the Trump administration, despite initial exemptions for pharma from August's Swiss tariffs.

This deal aligns with Novartis's recent aggressive M&A strategy, following the November 2024 acquisition of Kate Therapeutics for similar neuromuscular diseases, the $3.1 billion Anthos Therapeutics deal for cardiovascular offerings, and the $1.7 billion Regulus Therapeutics acquisition for kidney disorders. This consistent pattern underscores Novartis's commitment to external innovation and portfolio diversification.

Key Decisions for Investors

• Novartis (NVS) investors should recognize this acquisition as a strategic pipeline enhancement addressing patent cliffs and strengthening its rare disease portfolio, potentially supporting long-term growth outlooks.
• Avidity Biosciences (RNA) shareholders should capitalize on the significant acquisition premium while evaluating the investment potential of the newly formed Spinco, which will focus on early-stage precision cardiology programs.
• Institutional investors should continue monitoring M&A activity within the pharmaceutical sector, particularly deals driven by pipeline diversification, patent expiry mitigation, and strategic geographical positioning in response to trade policy uncertainties.